Acelrx Pharmaceuticals Inc. didn't have to wait for its Sunday PDUFA date for Zalviso, but the company also didn't receive the FDA approval it sought and analysts largely expected. Instead, the FDA late Friday issued a complete response letter (CRL) for the pain management product, seeking more information about the device to ensure proper use.